Table 159-3Secondary Acute Myelogenous Leukemia

Alkylating Agent RelatedEpipodophyllotoxin Related
PresentationMyelodysplasiaM4/M5 AML, some M1,M2
Latent period4–7 years1–3 years
Cytogeneticsdel (5q), del (7q), -5, -7Translocations, usually involving 11q23
Frequency1% to > 20%2% to 12%
OutcomePoorPoor
Preleukemic phaseCommonRare
AgeTypically olderYounger
PredispositionGerm line p53 and NF-1 mutations, GSTT1 null genotypeUnknown

AML = acute myelogenous leukemia.

From: Therapy-Related Secondary Cancers

Cover of Holland-Frei Cancer Medicine
Holland-Frei Cancer Medicine. 6th edition.
Kufe DW, Pollock RE, Weichselbaum RR, et al., editors.
Hamilton (ON): BC Decker; 2003.
Copyright © 2003, BC Decker Inc.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.